Active Ingredient(s): Osilodrostat Phosphate
FDA Approved: * March 6, 2020
Pharm Company: * RECORDATI RARE
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Isturisa Overview

Osilodrostat, sold under the brand name Isturisa, is a medication for the treatment of adults with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease.[1] It is taken by mouth.[1] The most common side effects are adrenal insufficiency, headache, vomiting, nausea, fatigue, and edema (swelling caused by fluid retention).[1][2] Hypocortisolism (low cortisol lev...

Read more Isturisa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Isturisa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Osilodrostat Phosphate
  • Tablet: 10mg, 1mg, 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Isturisa: (3 results)

Sorted by National Drug Code
  • 55292-320 Isturisa 1 mg Oral Tablet, Coated by Recordati Rare Diseases, Inc.
  • 55292-321 Isturisa 5 mg Oral Tablet, Coated by Recordati Rare Diseases, Inc.
  • 55292-322 Isturisa 10 mg Oral Tablet, Coated by Recordati Rare Diseases, Inc.

Other drugs which contain Osilodrostat Phosphate or a similar ingredient: (1 result)